Want to see CTOR full AI Analyst Report?
CTOR Stock Chart & Stats
$1.07
-$0.06(-4.78%)
At close: 4:00 PM EST
$1.07
-$0.06(-4.78%)
Day’s Range― - ―
52-Week Range$0.49 - $3.20
Previous CloseN/A
Volume120.49K
Average Volume (3M)60.02K
Market Cap
$67.07M
Enterprise Value$62.55M
Total Cash (Recent Filing)$2.63M
Total Debt (Recent Filing)$3.80M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume54,313
30 Day Avg. Volume60,024
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue11.15
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$4.00Price Target Upside273.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$20.82M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityLow absolute debt and a debt-to-equity ratio near 0.08–0.09 give the company structural financial flexibility. This reduces near-term solvency pressure and preserves borrowing capacity to fund clinical programs and commercialization efforts over the next several quarters without immediate high interest burden.
Commercial Expansion Of LYMPHIRLaunching LYMPHIR in the U.S. and initiating European named-patient distribution establishes initial commercial channels and payer engagement. Those durable market-access steps help build prescriber relationships, supply chains, and incremental revenue opportunities beyond one quarter as the company scales targeted oncology commercialization.
Promising Clinical Data Supporting Label ExpansionPositive investigator-led Phase 1 activity with a 24% ORR and durable responses in heavily pretreated patients supports advancement into Phase 2 and potential label expansion beyond CTCL. Progressing the program and translational work can materially expand addressable markets and the long-term commercial opportunity if confirmed in larger trials.
Bears Say
Pre-revenue With Widening Operating LossesSustained operating losses with no revenue base mean the company must rely on capital markets or debt to fund operations. Continued negative profitability erodes equity and increases financing needs, constraining strategic optionality and raising execution risk if commercial uptake or trial readouts don't accelerate.
Weak And Worsening Cash GenerationNegative operating and free cash flow that have meaningfully worsened indicate accelerating cash burn. This structural cash gap increases the probability of dilutive financings or onerous debt terms, which can compress capital available for R&D and commercialization over the next several quarters absent revenue inflection.
Nasdaq Non-compliance And Delisting RiskA Nasdaq non-compliance notice poses a durable governance and liquidity risk: potential delisting would impair access to many institutional investors, reduce secondary liquidity, and make future capital raises more costly or difficult, which directly affects the company's ability to fund clinical and commercial plans.
Citius Oncology News
CTOR FAQ
What was Citius Oncology, Inc.’s price range in the past 12 months?
Citius Oncology, Inc. lowest stock price was $0.49 and its highest was $3.20 in the past 12 months.
What is Citius Oncology, Inc.’s market cap?
Citius Oncology, Inc.’s market cap is $67.07M.
When is Citius Oncology, Inc.’s upcoming earnings report date?
Citius Oncology, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Citius Oncology, Inc.’s earnings last quarter?
Citius Oncology, Inc. released its earnings results on May 15, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.26.
Is Citius Oncology, Inc. overvalued?
According to Wall Street analysts Citius Oncology, Inc.’s price is currently Undervalued.
Does Citius Oncology, Inc. pay dividends?
Citius Oncology, Inc. does not currently pay dividends.
What is Citius Oncology, Inc.’s EPS estimate?
Citius Oncology, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Citius Oncology, Inc. have?
Citius Oncology, Inc. has 92,981,200 shares outstanding.
What happened to Citius Oncology, Inc.’s price movement after its last earnings report?
Citius Oncology, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -14.019%.
Which hedge fund is a major shareholder of Citius Oncology, Inc.?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (273.83% Upside)
$4.00 (273.83% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 14.8%
Last 30 Days ▼ 14.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.38%
12-Months-Change
Fundamentals
Return on Equity
-99.47%
Trailing 12-Months
Asset Growth
10.13%
Trailing 12-Months
Company Description
Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$4.00
▲(273.83% Upside)
Technical Analysis
Ownership Overview
6.58% Insiders
0.79% Mutual Funds
9.88% Other Institutional Investors
82.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---